# Krystal Biotech, Inc. Common Stock (KRYS) — Stock CV

Krystal Biotech, Inc. is a $9.82B healthcare company. Revenue grew 22.6% over the last year, it keeps 55¢ of every dollar of sales as profit, and it holds more cash than debt. It trades at 40.6× earnings — around the middle of its own history.

> Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs.

## Identity

- **Ticker**: KRYS
- **Sector**: Healthcare
- **Industry**: Biological Products, (No Diagnostic Substances)
- **Headquarters**: PITTSBURGH, PA
- **Employees**: 295
- **Website**: https://www.krystalbio.com
- **Market cap**: $9.82B
- **Last price**: $331.61
- **Financial profile**: Strained

## Vitals (TTM)

- **Revenue**: $440M
- **Net income**: $241M
- **Free cash flow**: $258M
- **Net cash**: $818M
- **P/E**: 40.6
- **Revenue growth (YoY)**: 22.6%

## Skills (profile scores, 0–100)

| Pillar | Score |
|---|---|
| Valuation | 25 |
| Growth | 0 |
| Profitability | 95 |
| Health | 50 |
| Quality | 60 |
| Moat | 50 |

## Qualifications (beginner checklist) — 7 of 10 passed

- [x] Revenue growing — +22.6% YoY
- [x] Profitable — $241M TTM
- [x] Profit growing — +129.7% YoY
- [x] Generates cash — $258M TTM
- [x] Debt under control — more cash than debt
- [x] Established company — $9.82B market cap
- [ ] Not printing shares — +34.9% shares over ~5y
- [ ] Proven track record — 3/8 profitable years
- [ ] Financially stable — health score 25/100
- [x] Valuation not extreme — P/E 40.6

## Experience (career milestones)

- **FY2025** — Best year on record: $205M net income
- **FY2023** — Turned profitable: $10.9M net income after a loss year

## Strengths

- High gross margin (94.6%)
- Strongly profitable — 54.8% net margin
- Revenue growing 22.6% year over year
- Strong cash conversion — FCF is 58.5% of revenue
- Net cash position after subtracting debt from cash

## Watch-outs

- Thin interest coverage (-52.5×)
- Loss-making in 5 of the recent years

## Track record

| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| FY2021 | — | -$69.6M | -$116M |
| FY2022 | — | -$140M | -$154M |
| FY2023 | $50.7M | $10.9M | -$101M |
| FY2024 | $291M | $89.2M | $119M |
| FY2025 | $389M | $205M | $189M |

---

Source: https://stockcv.com/KRYS — derived from company filings; may be delayed or incomplete. Information, not investment advice.